2022 World Conference on Lung Cancer (Posters)-P1.11-02. Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C

P1.11-02. Combined Regimen of Anlotinib and Trametinib for NSCLC Patients Harbouring Pan-KRAS Mutation without KRASG12C

Pdf Summary

Researchers from Shanghai Jiao Tong University Affiliated Chest Hospital in China have developed a combination treatment strategy for non-small cell lung cancer (NSCLC) patients with pan-KRAS mutation but without the commonly targeted KRASG12C mutation. KRAS mutation is a common alteration in NSCLC, but until recently, inhibitors targeting KRASG12C have been the only effective treatment option, covering only 13% of NSCLC cases. The combination strategy evaluated in this study involved using a MEK inhibitor called trametinib and a multi-targeted tyrosine kinase inhibitor called anlotinib. <br /><br />In preclinical experiments, the combined treatment showed promising results by blocking the MEK pathway and targeting anlotinib-covered targets in pan-KRAS mutant NSCLC. Furthermore, a phase I clinical trial was conducted to evaluate the safety and efficacy of the combination regimen in NSCLC patients with pan-KRAS mutation without KRASG12C. The trial showed that 6 out of 10 patients had a significant response after receiving at least one cycle of combination treatment.<br /><br />The study suggests that the combination of anlotinib and trametinib could be an effective strategy against NSCLC patients with pan-KRAS mutation, even without the presence of KRASG12C. Both in vitro and in vivo experiments demonstrated that the combination treatment had stronger anti-tumor effects on different KRAS mutant NSCLC cases.<br /><br />This research provides evidence for the potential clinical value of this novel combination therapy approach and highlights an alternative treatment strategy for NSCLC patients with pan-KRAS mutation. The study's findings contribute to expanding treatment options for a significant portion of NSCLC patients who do not have the commonly targeted KRAS mutation.

Asset Subtitle

Baohui Han, China

Meta Tag

Speaker Baohui Han, China

Topic Locally Advanced Non-small Cell Lung Cancer - Neoadjuvant and Adjuvant Therapy

Keywords

Shanghai Jiao Tong University

combination treatment strategy

non-small cell lung cancer

pan-KRAS mutation

KRASG12C mutation

MEK inhibitor

trametinib

multi-targeted tyrosine kinase inhibitor

anlotinib

alternative treatment strategy